Document ID: chunk:federal_register_of_legislation:F2025L00067:schedule:1:p2
Version: federal_register_of_legislation:F2025L00067
Segment Type: schedule
Provision Reference: sch 1 (pt 2/2)
Character Range: 5994–6525

cell death ligand-1 (PD-L1) inhibitor for non-small cell lung cancer; AND
                               Patient must have a WHO performance status of 0 or 1; AND
                               The condition must not have evidence of an activating epidermal growth factor receptor (EGFR) gene or an anaplastic lymphoma kinase (ALK) gene rearrangement or a c-ROS proto-oncogene 1 (ROS1) gene arrangement in tumour material; AND

                               The treatment must not exceed a total of 7 doses under this restriction.